The obesity peptide that is not a GLP-1 comes from inside your mitochondria

MOTS-C, a peptide encoded inside mitochondrial DNA rather than in the nucleus, was one of seven peptides an FDA advisory committee put on its July 23 and July 24, 2026 agenda. Scientists are separately recruiting adults with obesity and prediabetes for a 12-week clinical trial.

Interest comes from where it lives and what it switches on. First identified in 2015, MOTS-C is thought to mimic many of the biological effects of exercise, mainly by activating AMPK, the enzyme that governs energy balance in cells and, once switched on, stimulates glucose uptake, increases fat metabolism and boosts mitochondrial function.

Evidence underneath that idea is thin. Animal work and limited human data suggest it could stop insulin resistance and diet-induced obesity, and one combined animal and human study found improvements in gait and grip strength. It is not approved for human use, and the endurance reports circulating on message boards are anecdotes rather than laboratory results.

Two things would move it out of forum lore. The next proof step is that trial, and after it, whether MOTS-C reaches the 503A Bulks List, the inventory of ingredients pharmacists and doctors can use in compounded medicines. Meanwhile zone 2 work for 80 percent of a session still improves mitochondrial function and costs nothing.

Read the full story at Men's Health ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.